Previous 10 | Next 10 |
home / stock / alpmf / alpmf news
Astellas Pharma press release (OTCPK:ALPMF): FY GAAP EPS of ¥103.03. Revenue of ¥1296.16B (+3.7% Y/Y) beats by ¥1285.85B. For further details see: Astellas Pharma GAAP EPS of ¥103.03, revenue of ¥1296.16B beats by ¥1285.85B
ESSA Pharma developed a novel mode of action drug, EPI-7386, for the treatment of metastatic castrate-resistant prostate cancer. Pre-clinical and early Ph 1 results are promising. ESSA's share price crashed in mid-Aug when a change in the Ph 1 trial protocol was announced, and a delay...
Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, trusts, and offshore funds. Tweedy,...
Astellas Pharma (OTCPK:ALPMF): 1H Non-GAAP EPS of ¥53.30; GAAP EPS of ¥38.65. Revenue of ¥651.66B (+5.9% Y/Y) Press Release For further details see: Astellas Pharma reports 1H results
Astellas Pharma (OTCPK:ALPMY) and Seagen (NASDAQ:SGEN) have announced that Japan's Ministry of Health, Labour and Welfare has approved PADCEV (enfortumab vedotin) for radically unresectable urothelial carcinoma that has progressed after anti-cancer chemotherapy. The New Drug Application ...
Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious, rare, and life-threatening diseases. Acer submitted an NDA for its lead drug candidate ACER-001 for treatment of UCDs in early August. Acer expects notification ...
Raymond James has upgraded FibroGen (NASDAQ:FGEN) to market perform from underperform after the company joined Astellas Pharma (OTCPK:ALPMF) on Thursday to announce the European approval of EVRENZO (roxadustat) for adults with anemia linked to chronic kidney disease (CKD). FibroGen (FGEN...
The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Astellas Pharma Inc. 2021 Q2 - Results - Earnings Call Presentation
The U.S. FDA has granted Astellas Pharma ([[ALPMF]]) and Seagen's ([[SGEN]] -0.4%) PADCEV (enfortumab vedotin-ejfv) expanded approval for a new indication to treat certain patients with urothelial cancer.The approval allows for the use of PADCEV for adult patients with locally advan...
AstraZeneca's innovative culture earned it a place as one of the leading biotechs globally. Revenue growth from COVID vaccine sales and some key markets provide strong tailwinds for the company's share in the second half of 2021. Most of AstraZeneca's revenue comes from a handful ...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc Company Name:
ALPMF Stock Symbol:
OTCMKTS Market:
Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...
One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca 's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive...
This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ...